NCT07044141 (NB-UVB) is a Phase 1 clinical trial of Azathioprine in Vitiligo, sponsored by Lahore General Hospital.

Who is sponsoring NCT07044141?

NCT07044141 is sponsored by Lahore General Hospital.

What drugs are being tested in NCT07044141?

Interventions in NCT07044141: Azathioprine, Tofacitinib.

Is NCT07044141 still recruiting?

NCT07044141 is currently active, enrolled. Last updated 29 June 2025.

Last reviewed 2025-06-29 · How we verify

NCT07044141: NB-UVB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Oral Tofacitinib in Combination of Narrow Band UVB in Treatment of Vitiligo

Active, enrolled Phase 1 Last updated 29 June 2025

What this trial tests

Phase 1 trial testing Azathioprine in Vitiligo in 20 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 March 2025

Primary endpoint
30 September 2025

30 September 2025

Quick facts

Lead sponsor	Lahore General Hospital
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 March 2025
Primary completion	30 September 2025
Estimated completion	30 September 2025
Sites	1 location across Pakistan

Drugs / interventions tested

Azathioprine (AZATHIOPRINE) — full drug profile →
Tofacitinib (tofacitinib) — full drug profile →

Conditions studied

Vitiligo — all drugs for Vitiligo →

Sponsor

Lahore General Hospital

Who can join

Adults 18 to 60, any sex, with Vitiligo. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

20 patients will be enrolled. All were given narrowband UVB . 10 wil be give oral azathriopfine . 10 will be given tofacitinib

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Azathioprine

Trials testing the same drug.

NCT07271069 — Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis · recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT07168161 — BDB-001 Phase III Trial in ANCA-Associated Vasculitis · Phase 3 · recruiting
NCT06476366 — Comparison of Efficacy of Methotrexate and Azathioprine in Patients With Chronic Actinic Dermatitis: A Randomized Contro · EARLY_PHASE1 · completed
NCT05349006 — Azathioprine in MOGAD · Phase 3 · recruiting

Other recruiting trials for Vitiligo

Currently open trials in the same condition.

NCT07153666 — A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo · recruiting
NCT07267273 — Betamethasone Phonophoresis For Vitiligo · NA · recruiting
NCT07232238 — TRPM2 Gene Polymorphism, NLRP3 Inflammasome Expression in Vitiligo Patients · active not recruiting
NCT07532330 — Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo · NA · active not recruiting
NCT07357870 — A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo · Phase 1 · recruiting

Other Lahore General Hospital trials

Trials by the same sponsor.

NCT07470359 — Comparison of Functional Outcomes Following Arthroscopic ACL Reconstruction With Peroneus Longus Autograft With and With · Phase 2 · recruiting
NCT07261306 — Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis · EARLY_PHASE1 · recruiting
NCT07112898 — Effect of Platelet-Rich Plasma on Graft Uptake and Postoperative Outcomes in Full-Thickness Skin Grafting of Face and Ne · NA · enrolling by invitation
NCT07478874 — Prophylaxis Against Surgical Site Infections Using Local as Well as Systemic Antibiotic · NA · completed
NCT07460908 — Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07044141 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lahore General Hospital
Last refreshed: 29 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07044141.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing